Galactosylated solid lipid nanoparticles with cucurbitacin B improves the liver targetability.

Area of Science:

• Nanotechnology
• Drug Delivery
• Hepatology

Background:

• Solid lipid nanoparticles (SLNs) are promising drug delivery systems.
• Targeting specific organs like the liver can improve therapeutic efficacy.
• Cucurbitacin B (Cuc B) is a hepatoprotective compound with potential therapeutic applications.

Purpose of the Study:

• To prepare liver-targeting SLNs loaded with cucurbitacin B (Cuc B).
• To evaluate the enhanced liver targeting and cytotoxicity of galactosylated SLNs (GalSLN) compared to conventional SLNs (CSLN).

Main Methods:

• Synthesis of N-hexadecyl lactobionamide (N-HLBA), a galactosylated lipid.
• Preparation of Cuc B-loaded GalSLN and CSLN using high-pressure homogenization.
• Characterization of SLN physical and pharmaceutical properties (particle size, zeta potential, in vitro release).
• Assessment of in vitro cellular cytotoxicity and in vivo liver targeting efficiency.

Main Results:

• Both GalSLN and CSLN exhibited similar physical properties and biphasic drug release.
• Encapsulation of Cuc B in SLNs enhanced its cytotoxic activity.
• GalSLN demonstrated significantly higher liver targeting efficiency (63.6%) compared to CSLN (25.3%) and Cuc B solution (23.8%).
• GalSLN showed enhanced cellular accumulation and cytotoxicity due to the galactosyl ligand.

Conclusions:

• The incorporation of N-HLBA into SLNs significantly enhances liver targetability.
• GalSLN represents a promising drug delivery carrier for improved liver targeting of Cuc B.
• This approach holds potential for enhanced treatment of liver diseases.